drugset / Trial / NCT02213887
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
Non-randomizedSingle-groupOpen-labelOther
Summary
The purpose of this 9-day study is to determine if: 1. Pantoprazole modifies the steady-state plasma concentrations of orally administered psychotropic medications including valproic acid, lithium, and second-generation antipsychotics (i.e., aripiprazole, asenapine, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone) 2. Serum gastrin levels change within a week of starting or stopping pantoprazole
Timeline
- Start
- 2014-09
- Primary completion
- 2020-11-02
- Completion
- 2020-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pantoprazole | Other / unclassified | 0 mg | Oral |
| Subject | Pantoprazole | Other / unclassified | 40 mg | Oral |